/DISREGARD RELEASE: IASO Bio/

We are advised by IASO Bio that journalists and other readers should disregard the news release, IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics, issued 13-Aug-2026 over PR Newswire, as the release contained erroneous information.

Subscribe on LinkedIn

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.